InsiderTrades

Form 4 for BVS Bioventus Inc.

Accepted 2022-04-05 00:00:00 ET · period of report 2022-04-01 · accession 0000899243-22-013963 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-04-05 2022-04-04 BVS Nosenzo John Chief Commercial Off S - Sale+OE $11.12 -66.0K 83.9K -44% -$733.5K
D 2022-04-05 2022-04-01 BVS Nosenzo John Chief Commercial Off M - OptEx — +106.5K 149.9K +245% —
D 2022-04-05 2022-04-01 BVS Nosenzo John Chief Commercial Off M - OptEx $0.00 -106.5K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Class A Common Stock 2022-04-04 S D 65,963 $11.12 83,932 D — — (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.48, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
2 Common Class A Common Stock 2022-04-01 M A 106,485 — 149,895 D — — (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. (F2) Includes 40 shares acquired under the Company's 2021 Employee Stock Purchase Program on April 1, 2022.
3 Derivative Restricted Stock Units 2022-04-01 M D 106,485 $0.00 0 D — · — to — 106,485 Class A Common Stock (F5) The RSUs vested on April 1, 2022.